Dyne Therapeutics, Inc. (DYN) jumped 41.24% to $24.18, gaining $7.06, after Jefferies analysts said the company could benefit from Novartis' acquisition of Avidity Biosciences. Analysts noted that the deal validates the potential of RNA-based therapies for neuromuscular diseases, an area where Dyne is advancing its own clinical programs.
The firm said the acquisition underscores "strategic interest and long-term value" in RNA therapeutics, boosting investor confidence in Dyne's platform. Shares of Avidity have gained 140% year-to-date following the announcement, while Dyne's stock has rebounded into positive territory for 2025.
On Monday, DYN opened at $18.75, reached a high of $24.50 and a low of $18.60, compared to a previous close of $17.12 on the NasdaqGS. Trading volume surged well above average. The stock's 52-week range is $9.65 - $30.27.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.